Biancamaria Saracino

Biancamaria Saracino

Auto-generated profile, based on publicly available information

Biancamaria Saracino

Department of Radiotherapy, Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2009 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SMSimona Marzi
Simona Marzi
BSBiancamaria Saracino
Biancamaria Saracino
MPMaria G Petrongari
Maria G Petrongari
SASTEFANO ARCANGELI
STEFANO ARCANGELI
SGSara Gomellini
Sara Gomellini
VVValeria Vandoni
Valeria Vandoni
Recently, the use of hypo-fractionated treatment schemes for the prostate cancer has been encouraged due to the fact that α/β ratio for prostate cancer should be low. However a major concern on the use of hypofractionation is the late rectal toxicity, it is important to be able to predict the risk of toxicity for alternative treatment schemes, with the best accuracy. The main purpose of this study is to evaluate the response of rectum wall to changes in fractionation and to quantify the α/β ratio for late rectal toxicity

24 October 2013 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VVValeria Vandoni
Valeria Vandoni
CGCarolina Giordano
Carolina Giordano
AMAnnelisa Marsella
Annelisa Marsella
BSBiancamaria Saracino
Biancamaria Saracino
MPMaria Grazia Petrongari
Maria Grazia Petrongari
PPPaola Pinnarò
Paola Pinnarò
Feasibility of whole breast hypofractionated radiotherapy schedules in breast conserving therapy is recognized however concerns remain about the role of the boost dose on the overall treatment’s potential toxicity. In this study we report on the possibility to quantitatively evaluate radiation induced toxicity in patients treated with an abbreviated course with major concern in the irradiated boost region.

1 July 2008 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
BSBiancamaria Saracino
Biancamaria Saracino
MGMichele Gallucci
Michele Gallucci
PCPiero De Carli
Piero De Carli
ASAntonella No Soriani
Antonella No Soriani
RPRocco Papalia
Rocco Papalia
GAGiorgio Arcangeli
Giorgio Arcangeli

28 June 2014 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
BSBiancamaria Saracino
Biancamaria Saracino
MPMaria Grazia Petrongari
Maria Grazia Petrongari
SMSimona Marzi
Simona Marzi
VBVicente Bruzzaniti
Vicente Bruzzaniti
GSGomellini Sara
Gomellini Sara
LSLidia Strigari
Lidia Strigari
The aim of the study was to report the clinical results in patients with high-risk prostate cancer treated with pelvic intensity-modulated radiation therapy (IMRT) and simultaneous integrated boost (SIB) to the prostate area. A total of 110 patients entered our study, 37 patients presented with localized prostate cancer and radiological evidence of node metastases or ≥15% estimated risk of lymph node (LN) involvement, while 73 patients underwent postoperative adjuvant or salvage irradiation for biochemical or residual/recurrent disease, LN metastases, or high risk of harboring nodal metastases. All patients received androgen deprivation therapy (ADT) for 2 years. The median follow-up was 56.5 months. For the whole patient group, the 3- and 5-year freedom from biochemical failure were 82.6% and 74.6%, respectively, with a better outcome in patients treated with radical approach. The 3- and 5-year freedom from local failure were 94.4% and 90.2%, respectively, while the 3- and 5-year distant metastasis-free survival were 87.8% and 81.7%, respectively. For all study patients, the rate of freedom from G2 acute rectal, intestinal, and urinary toxicities was 60%, 77%, and 61%, respectively. There was no G3 acute toxicity, ≥G2 late intestinal toxicity, or G3 late urinary or rectal toxicity. The 3- and 5-year ≥G2 freedom from late rectal toxicity rate were 98% and 95%, respectively, while the 3- and 5-year ≥G2 freedom from late urinary toxicity rate were 95% and 88%, respectively. The study concludes that pelvic IMRT and SIB to the prostatic area in association with 2-year ADT was a well-tolerated technique, providing high disease control in patients with prostate cancer requiring LN treatment.

13 October 2008 in Medical Physics
Verified
Journal Article
Closed access
LSLidia Strigari
Lidia Strigari
AMAnnelisa Marsella
Annelisa Marsella
SCStefano Canitano
Stefano Canitano
SGSara Gomellini
Sara Gomellini
SASTEFANO ARCANGELI
STEFANO ARCANGELI
GAGiorgio Arcangeli
Giorgio Arcangeli